Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients

Exclusion Criteria

• •Who have a history of allergy to vitamin D3 derivative preparations or a history of relevant drug hypersensitivity.
• •BMI \> 32.0 kg/m2
• •Who are pregnant or lactating.
• •Who have any renal or hepatic insufficiency, or clinically significant cardiac, renal or hepatic disease.
• •Who are not deemed eligible as determined by medical history, physical examination or clinical laboratory safety tests.
• •Who have clinically relevant history or presence of any disease or surgical history other than psoriasis which is likely to affect the conduct of the study.
• •Whose serum calcium levels exceed the upper limit of reference range
• •Who have used any investigational medicinal product and/or participated in any clinical study within 60 days of randomization.
• •Who have taken any durg with known effects on calcium metabolism within 30days of randomization
• •Who have been treated with any drug with a known risk of QT prolongation within 30days of randomization.